If you have PCOS, a GLP-1 medication like semaglutide or tirzepatide can be one of the most effective tools for the two things that drive most of your symptoms: excess weight and insulin resistance. In recent real-world data, women with PCOS lost far more weight on a GLP-1 than on metformin, and losing weight often helps regulate cycles, support ovulation, and ease androgen symptoms like acne and unwanted hair growth. No GLP-1 is FDA-approved specifically for PCOS, so this is an off-label use that a licensed provider should guide. Here is the full, honest picture.
Key takeaways
- PCOS is driven largely by insulin resistance and weight, and GLP-1 medications target both at once, which is why they help with more than just the number on the scale.
- The weight-loss edge over metformin is large. In a 2025 analysis of more than 36,000 women with PCOS, GLP-1 users lost a median of 11.5% of body weight at one year versus 1.9% on metformin.
- Weight loss can restore cycles and support fertility. GLP-1s improved menstrual regularity and natural pregnancy rates in a meta-analysis, but they are not fertility drugs, and they are not safe in pregnancy.
- No GLP-1 is FDA-approved for PCOS. Wegovy and Zepbound are approved for weight management; Ozempic and Mounjaro are approved for type 2 diabetes. PCOS use is off-label for all of them.
- These are real medications with real cautions, including a boxed warning for thyroid tumors. A licensed provider should review your history first.
What is PCOS, and why does weight matter so much?
Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions in women of reproductive age, affecting roughly 1 in 8 to 1 in 10 women. Despite the name, it is not really about cysts. It is a whole-body hormonal and metabolic condition, and at its center, for most women, is insulin resistance.
Here is the chain of events that ties it together:
- Your cells stop responding well to insulin, so your body makes more of it.
- High insulin pushes the ovaries to make more androgens (male-pattern hormones like testosterone).
- Excess androgens are what drive the classic symptoms: irregular or missing periods, trouble ovulating, acne, and unwanted hair growth (or hair thinning).
- Higher insulin also makes it easier to gain weight and harder to lose it, and extra weight worsens insulin resistance, which feeds the whole cycle again.
That loop is the reason weight plays such an outsized role in PCOS. When you improve insulin sensitivity and lose weight, the loop often loosens: androgens fall, cycles can become more regular, and ovulation can return. This is why weight-focused treatment is not "just cosmetic" in PCOS, it is aimed straight at the mechanism.
How do GLP-1 medications help PCOS?
GLP-1s help because they work on both of the levers that matter most in PCOS: weight and insulin.
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after you eat. Medications like semaglutide and tirzepatide mimic that hormone at a steady, longer-lasting level, and they do several things at once:
- Quiet appetite and "food noise," so you feel hungry less often.
- Increase fullness, so meals get smaller without white-knuckle willpower.
- Slow how fast your stomach empties, which stretches out that full feeling.
- Steady blood sugar and improve insulin sensitivity, which is the part that matters most for PCOS.
For PCOS, the improvement in insulin and the weight loss are the point, and the reproductive benefits (more regular cycles, better ovulation, calmer androgen symptoms) mostly follow from there. That is an important distinction: a GLP-1 is not correcting PCOS at the ovary directly. It is fixing the metabolic engine that is driving your symptoms, and your hormones often respond.
How much weight can women with PCOS lose on a GLP-1?
More than on the older first-line options, based on the data we have. The clearest PCOS-specific picture comes from a 2025 Epic Research analysis of more than 36,000 women with PCOS who started either a GLP-1 or metformin. At one year:
- GLP-1 users lost a median of 11.5% of their body weight, compared with 1.9% on metformin.
- 55.7% of GLP-1 users reached at least 10% weight loss, versus 13.7% of metformin users.
- GLP-1 users were also more likely to see their A1C (a blood-sugar marker) improve.
Smaller clinical studies point the same direction. In a 2023 study published in the Journal of Clinical Medicine, 27 women with obesity and PCOS who had not responded to lifestyle changes took low-dose semaglutide; over six months, their mean weight loss was about 11.5 kg (roughly 25 pounds), and average BMI dropped from 34.4 to 29.4.
A few honest caveats belong right next to those numbers:
- Individual results vary. These are group averages, not a promise for any one person. Your result depends on your starting point, your dose, how your body responds, and daily inputs like protein, movement, and sleep.
- Much of the strongest weight-loss evidence comes from branded, FDA-approved medications studied in large trials, not from compounded versions, which have not been through those trials.
- Weight loss is not linear. Plateaus are normal. If the scale stalls, that is a signal to troubleshoot with your provider, not to quit.
GLP-1 vs metformin for PCOS: what's the difference?
Metformin has been a first step for PCOS for years, and it still has a real role, it is inexpensive, well understood, and helpful for the metabolic side of PCOS. The 2023 International Evidence-based Guideline for PCOS recommends metformin for adults with PCOS and a higher BMI to help with weight and metabolic features, and it says anti-obesity medications (the category that includes GLP-1s) may be considered alongside lifestyle changes.
The difference shows up most clearly in weight loss, where the newer GLP-1 data are striking.
| GLP-1 (semaglutide, tirzepatide) | Metformin | |
|---|---|---|
| Median weight loss at 1 year (PCOS)\* | ~11.5% | ~1.9% |
| Reached at least 10% weight loss\* | 55.7% | 13.7% |
| Main job | Appetite, fullness, insulin sensitivity, weight | Insulin sensitivity, metabolic features |
| Effect on cycles/ovulation | Often improves, mainly through weight + insulin | Can help, generally more modest |
| FDA-approved for PCOS? | No (off-label) | No (off-label; long used) |
| Cost | Higher | Low |
\*2025 Epic Research analysis of more than 36,000 women with PCOS.
This does not make metformin obsolete. Some women do well on it, some can't tolerate a GLP-1, and the two are sometimes used together. But if meaningful weight loss is a priority, and in PCOS it usually is, GLP-1 medications clearly outperformed metformin in this group.
Can a GLP-1 help your periods, ovulation, and fertility with PCOS?
Often, yes, and this is one of the most meaningful parts of the story for women with PCOS. But it works indirectly, through weight loss and better insulin sensitivity, not through a direct action on your ovaries.
Periods and ovulation. As weight comes down and insulin improves, androgens tend to fall, and cycles often become more regular. In the 2023 Journal of Clinical Medicine study above, about 80% of the women who responded to semaglutide had their menstrual cycles normalize. A 2023 meta-analysis of 11 randomized trials (840 women with PCOS) found that GLP-1 medications significantly improved menstrual regularity and were associated with a higher natural pregnancy rate, along with better insulin resistance and lower testosterone. If your periods are your main concern, our guide to how GLP-1s affect your period goes deeper.
Fertility, read this part carefully. GLP-1s are not fertility drugs. But because restoring ovulation can make you fertile again, sometimes unexpectedly, women with PCOS have reported surprise pregnancies after starting one. This is the "Ozempic babies" phenomenon, and we cover it honestly in GLP-1s, fertility, and pregnancy.
Two safety points that matter here:
- GLP-1s are not safe in pregnancy or while breastfeeding. Current guidance is to stop the medication well before trying to conceive, usually about two months ahead, and to plan this with your provider.
- If you use the pill, the medication you choose matters. Tirzepatide's FDA label warns that it can make oral birth control less effective, so a backup or non-oral method is advised after starting and after each dose increase. Semaglutide carries no such warning. We break this down in tirzepatide vs semaglutide for PCOS.
Which GLP-1 is best for PCOS: semaglutide or tirzepatide?
There is no single "best", there is a better fit for your goals. Both are used off-label for PCOS, and they lead with different strengths. Semaglutide has more published PCOS-specific research on cycles and ovulation. Tirzepatide tends to produce more total weight loss, which itself improves many PCOS symptoms.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names | Wegovy (weight), Ozempic (diabetes) | Zepbound (weight), Mounjaro (diabetes) |
| How it works | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Weight loss in trials | ~15% over 68 wks (STEP 1) | ~20-21% over 72 wks (SURMOUNT-1) |
| PCOS cycle/ovulation data | More published | Thinner so far |
| Oral birth control | No interaction warning | Can lower pill effectiveness, use backup |
| Elara compounded price | From $247/mo, all-in | From $355/mo, all-in |
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
In head-to-head research on weight loss (a 2024 analysis in JAMA Internal Medicine), people on tirzepatide were more likely to reach meaningful weight-loss milestones than those on semaglutide. So if maximum weight loss is your priority, tirzepatide has the edge on paper; if cycle regularity, fertility timing, or cost is front of mind, semaglutide is a strong choice with more direct PCOS data. For the full decision framework, read our deep dive on tirzepatide vs semaglutide for PCOS.
Is any GLP-1 FDA-approved for PCOS?
No. No GLP-1 medication is FDA-approved specifically to treat PCOS. Using one for PCOS is off-label, a common, legal, and accepted practice when a licensed provider decides it fits your situation, but one that should always be clinician-guided and monitored.
It is worth being precise about what each drug is approved for, because the names get mixed up constantly:
- Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management.
- Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes; using them for weight loss is off-label.
The practical takeaway is the same either way: PCOS itself is not on any of these labels, which is exactly why a provider, not the internet, should make the call.
Compounded semaglutide and tirzepatide: how they fit in
Alongside branded options, many women choose compounded semaglutide or tirzepatide, largely for cost and access. These are prepared by a state-licensed compounding pharmacy and prescribed by a licensed clinician when appropriate for you, but you should understand exactly what they are.
About compounded medications: Compounded semaglutide and tirzepatide are prepared by a
state-licensed compounding pharmacy and prescribed by a licensed clinician when appropriate for you.
**Compounded medications are not FDA-approved and are not reviewed by the FDA for safety,
effectiveness, or quality.** They are not "generic" versions of Ozempic®, Wegovy®, Mounjaro®, or
Zepbound®. Talk to a licensed clinician about whether a compounded or FDA-approved option is right for you.
What are the risks, and who shouldn't take a GLP-1?
For most people, GLP-1s are well tolerated, but they are real medications with real cautions. The most common side effects are digestive, nausea, constipation, diarrhea, and reflux, and they tend to be worst when you first start or increase the dose, then ease over time. Starting low and titrating slowly is designed to limit them.
The serious risks you should know, per the FDA prescribing information:
- Boxed warning, thyroid C-cell tumors. In rodents, these medications caused thyroid C-cell tumors; whether they do so in humans is unknown. They are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Pancreatitis. Seek care for severe, persistent abdominal pain that may spread to your back.
- Gallbladder problems. Rapid weight loss can raise gallstone risk.
- Low blood sugar, more likely if you also take insulin or a sulfonylurea.
- Not for pregnancy or breastfeeding, a specific caution for women with PCOS, since fertility can return.
This is not a complete list, and PCOS treatment is not a self-serve decision. Talk to a licensed provider who can screen for contraindications, choose the right medication and dose, and monitor you over time. For full details, see the FDA prescribing information for Wegovy and Zepbound.
How Elara helps
Elara is a women-first telehealth program built for exactly this kind of decision. PCOS touches weight, insulin, cycles, birth control, and pregnancy plans all at once, and those are the details that get missed in a one-size-fits-all script. Here is how it works:
- A licensed provider reviews every patient, your history, your goals, and the things that matter for PCOS, like insulin resistance, cycles, thyroid concerns, birth control, and whether pregnancy is on your radar. Depending on your state and case, that review may be synchronous or asynchronous.
- If a GLP-1 is appropriate, it's prescribed, branded or compounded, semaglutide or tirzepatide, and shipped to your door from a licensed pharmacy.
- Everything is included in one cash-pay price: the provider visit, the medication, shipping, ongoing access to Elara's medical team, the private community, the Elara app, recipes, and workouts. 7-day-a-week human support, no insurance hurdles, available in all 50 states and Puerto Rico.
Brand-name Wegovy lists around $1,349 a month (NovoCare). Elara's compounded semaglutide program starts at $247/month, all-in (about $198/month on the 12-month plan), and compounded tirzepatide starts at $355/month. That is an honest comparison of price and access, not a claim of sameness. Compounded medications are not FDA-approved. To go deeper, read our women's guides to semaglutide and tirzepatide.
See whether a GLP-1 fits your PCOS, take Elara's free eligibility check. A licensed provider reviews every patient. Compounded medications are not FDA-approved.
Start your free eligibility check →
Frequently asked questions
Does semaglutide help PCOS? It can, indirectly. Semaglutide improves insulin sensitivity and drives weight loss, which lowers the androgens behind many PCOS symptoms, so periods can become more regular and acne or hair symptoms can ease. In one 2023 study, about 80% of women with PCOS who responded to semaglutide had their cycles normalize. It's used off-label; talk to a provider.
Is Wegovy approved for PCOS? No. Wegovy (semaglutide) is FDA-approved for chronic weight management, not for PCOS. No GLP-1 is FDA-approved specifically to treat PCOS, so any PCOS use is off-label. That is a normal and legal practice, but it should always be guided and monitored by a licensed clinician who knows your history.
Can a GLP-1 help you get pregnant with PCOS? Possibly, but not directly, GLP-1s are not fertility drugs. By restoring ovulation through weight loss and better insulin sensitivity, they can make pregnancy more likely, sometimes unexpectedly. Crucially, GLP-1s are not safe in pregnancy, so guidance is to stop about two months before trying to conceive. Plan this with your provider.
GLP-1 vs metformin for PCOS, which works better? For weight loss, GLP-1s clearly outperformed metformin in recent data: a 2025 Epic Research analysis of over 36,000 women with PCOS found a median 11.5% weight loss at one year on a GLP-1 versus 1.9% on metformin. Metformin is still useful for metabolic features and is sometimes combined with a GLP-1.
Which GLP-1 is best for PCOS? There is no single best, it depends on your goal. Semaglutide has more published PCOS data on cycles and ovulation; tirzepatide tends to produce more total weight loss. If you rely on the pill, note tirzepatide can reduce its effectiveness while semaglutide does not. A provider can match the medication to your priorities and health.
The bottom line
For PCOS, GLP-1 medications go after the root drivers, insulin resistance and weight, and in doing so they can improve cycles, ovulation, and androgen symptoms far more than metformin does for weight. No GLP-1 is FDA-approved for PCOS, and each carries real risks, so this is a decision to make with a licensed provider who can match the medication to your body and your goals. If you want a women-first program that takes PCOS seriously, a clinician reviews every Elara patient, with transparent, all-inclusive pricing.
References
- Epic Research. "GLP-1s Lead to Greater Weight Loss and A1C Improvement Than Metformin in Patients with PCOS." 2025. https://www.epicresearch.org/articles/glp-1s-lead-to-greater-weight-loss-and-a1c-improvement-than-metformin-in-patients-with-pcos/
- Carmina E, Longo RA. "Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs." Journal of Clinical Medicine, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531549/
- BMC Endocrine Disorders. "Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review." 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631119/
- Teede HJ, et al. "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome." Journal of Clinical Endocrinology & Metabolism, 2023. https://academic.oup.com/jcem/article/108/10/2447/7242360
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Rodriguez PJ, et al. "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity." JAMA Internal Medicine, 2024. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
- U.S. Food and Drug Administration. "WEGOVY (semaglutide) Prescribing Information," including boxed warning. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
- U.S. Food and Drug Administration. "ZEPBOUND (tirzepatide) Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf
- NovoCare. "Wegovy (semaglutide) cost and coverage." https://www.novocare.com/patient/medicines/wegovy.html
This article is for general education and is not medical advice. It doesn't replace a conversation
with a licensed clinician about your health, medications, or treatment. Reading it doesn't create a
doctor-patient relationship. If you have a medical emergency, call 911. See our full
Medical Disclaimer.
About compounded medications: Compounded semaglutide and tirzepatide are prepared by a
state-licensed compounding pharmacy and prescribed by a licensed clinician when appropriate for you.
**Compounded medications are not FDA-approved and are not reviewed by the FDA for safety,
effectiveness, or quality.** They are not "generic" versions of Ozempic®, Wegovy®, Mounjaro®, or
Zepbound®. Talk to a licensed clinician about whether a compounded or FDA-approved option is right for you.